Introduction {#s1}
============

*Staphylococcus aureus* is a commensal Gram-positive bacterium, which under certain circumstances may be responsible for pyogenic or toxigenic infections, such as skin and soft tissue infections, toxic shock syndrome and pneumonia (Tong et al., [@B78]). Its carriage is considered as an important risk factor for subsequent development of hospital and community-acquired infections (Ellis et al., [@B27]; Wertheim et al., [@B83]; Maier et al., [@B51]; Dukic et al., [@B23]; Levy et al., [@B44]). The anterior nares is recognized as the primary site for *S. aureus* colonization (Kluytmans et al., [@B42]; van Belkum et al., [@B81]; Sollid et al., [@B70]). Other anatomical niches for *S. aureus* include the skin (Popov et al., [@B61]), oropharynx (Mertz et al., [@B53]; Petersen et al., [@B60]), intestinal tract (Acton et al., [@B1]), and the vagina (Bourgeois-Nicolaos et al., [@B14]).

The importance of fecal carriage of *S. aureus* has been recognized more than five decades ago in a study which demonstrated that rectal *S. aureus* carriage preceded those from the nose and throat in new-borns (Hurst, [@B38]). Thereafter, several studies have provided evidence on the clinical importance of fecal carriage of *S. aureus* \[in particular methicillin-resistant *S. aureus* (MRSA)\] in the hospital setting (Acton et al., [@B1]). For example, it has been shown that hospitalized patients with both *S. aureus* fecal and nasal colonization are significantly more likely to have positive skin cultures compared to patients with nasal carriage only (Bhalla et al., [@B12]). In addition, *S. aureus* fecal carriage may serve as an important source for environmental contamination, which can potentially facilitate nosocomial transmission within the healthcare setting (Bhalla et al., [@B12]). Furthermore, antibiotic-associated diarrhea attributed to MRSA has also been reported (Lo and Borchardt, [@B49]; Sizemore et al., [@B69]; Avery et al., [@B5]); and patients with MRSA colonized diarrheal stools impact significantly on environmental contamination (Boyce et al., [@B15]).

Despite the potential role and significance of the sole fecal carriage of *S. aureus* (Lee et al., [@B43]; Squier et al., [@B72]; Bhalla et al., [@B12]) and the transmission dynamics of *S. aureus* in infection, a limited number of studies have focused on fecal *S. aureus* carriage in the hospital and community setting (Acton et al., [@B1]). This systematic literature review is therefore aimed to determine the overall rate of *S. aureus* \[including methicillin susceptible and resistant *S. aureus* (MSSA and MRSA)\] fecal carriage amongst individuals in the community and healthcare settings.

Methodology {#s2}
===========

This review followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (Moher et al., [@B55]). The PRISMA check-list for this review is provided in a Supplementary Table (Table [S1](#SM1){ref-type="supplementary-material"}).

Literature search strategy
--------------------------

Peer-reviewed articles (written in English and French) published through to 11 November 2015 on *S. aureus* fecal carriage within the community and healthcare settings were evaluated using four electronic databases and a combination of keywords (Table [1](#T1){ref-type="table"}). We also explored for additional articles by checking the references cited in the primary eligible studies included in this systematic review.

###### 

**Search strategy performed in four databases**.

  **Database**                                                                **Search mode**                     **Keywords**
  --------------------------------------------------------------------------- ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medline via Pubmed                                                          All fields                          ("staphylococcus aureus") AND ("gut" OR "gastrointestinal" OR "anal" OR "anus" OR "intestinal" OR "rectum" OR "rectal" OR "stool" OR "feces" OR "faeces" OR "fecal" OR "faecal") AND ("epidemiology" OR "incidence" OR "prevalence" OR "carriage" OR "carriage rate" OR carrier\*) AND ("humans" OR "human")
  Scopus via SciVerse                                                         Article title, abstract, keywords   
  Academic Search Premier, Africa-Wide Information and CINAHL via EBSCOHost   Boolean/Phrase                      
  Web of Science via Web of Knowledge                                         Topic                               

Study selection and data extraction
-----------------------------------

Potentially relevant articles (selected based on their titles and abstracts) were assessed for eligibility (Table [2](#T2){ref-type="table"}) by three independent authors. All potentially eligible articles were screened for "predatory journals" using "Beall\'s list" (Beall, [@B7]; Shen and Björk, [@B67]; Siebert et al., [@B68]). The corresponding authors of potentially relevant articles were contacted to determine the healthcare exposure status of participants so as to assess their eligibility for inclusion in this systematic review (Table [2](#T2){ref-type="table"}). Data extraction was performed independently by two authors using a standardized data extraction form. Disagreements and inconsistencies were resolved by consensus. The following information was extracted from each eligible study: study population, number of participants screened for fecal carriage, participant characteristics (age, health status, exposure to health care settings), sample collection details (sample type, age at which samples were collected, collection site), laboratory techniques (*S. aureus* and MRSA screening methods, genotyping techniques, virulence profile assessment), as well as *S. aureus* and MRSA detection rates.

###### 

**Eligibility criteria**.

  **Inclusion criteria for systematic review**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **Exclusion criteria for systematic review**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies published from 1920 to 11 November 2015 were included in the search.Studies reporting on *S. aureus* or MRSA carriage from fecal/rectal/anal specimens from humans.Studies providing information on the prevalence of *S. aureus* or MRSA fecal carriage.Healthcare exposure data should include information on whether or not participants were: Hospitalized in the 12 months prior to screening nursing home residents, health care workers, or patients transferred from other hospitals or wards (McKinnell et al., [@B52]).Screened for *S. aureus* or MRSA fecal carriage within \> or ≤48 hours of healthcare contact (Folden et al., [@B31]; Millar et al., [@B54]; Otter and French, [@B59]).Studies published in either English or French.   Studies screening for *S. aureus* or MRSA from samples other than feces/rectal swabs/anal swabs.Fecal samples studied for parasites or bacteria other than *S. aureus*.Articles reporting on the number of *S. aureus* or MRSA isolates detected from fecal specimens or on the number of fecal specimens positive for *S. aureus* or MRSA, but not providing information on the number of participants testing positive for *S. aureus* or MRSA fecal carriage.Studies not providing the necessary healthcare exposure data for participants (via the published article or via correspondence with the authors), in order to categorize participants into Healthy participants, Out-patients, In-patients and Healthcare personnel.Articles published in predatory journals (Beall, [@B7]).Articles not obtainable from the electronic databases, the University of Cape Town (UCT) library or the UCT inter-library loans.
  **Inclusion criteria for meta-analysis of proportions**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **Exclusion criteria for meta-analysis of proportions**
  Overall fecal carriage prevalence for *S. aureus* and/or MRSA must be available.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Studies providing fecal carriage rates for participants for which fecal carriage rates have previously been reported.Studies not providing information on the age at which participants were screened.Studies screening a pre-selected group of participants based on microbiological assessments.Studies for which MRSA was not confirmed using molecular methods.

Operational definitions of terms used in this systematic review
---------------------------------------------------------------

### Community setting

#### Healthy participants

-   Participants reported to be healthy at the time of screening for *S. aureus* or MRSA fecal carriage without any exposure to healthcare settings during the year preceding screening (McKinnell et al., [@B52]);

-   Pregnant women visiting obstetric clinics;

-   New-borns and mothers at maternity wards during the time of delivery;

-   Mothers and infants reported as healthy at the time of screening for *S. aureus* or MRSA fecal carriage, but exposed to the delivery unit or maternity ward during the year preceding screening.

#### Out-patients

Patients screened for *S. aureus* or MRSA fecal carriage with ≤48 h of healthcare contact (Folden et al., [@B31]; Millar et al., [@B54]; Otter and French, [@B59]). Patients should not have had contact with healthcare settings in the year preceding the study.

### Healthcare setting

#### In-patients

Patients screened for *S. aureus* or MRSA fecal carriage with \>48 h of healthcare contact. Patients screened within ≤48 h after admission should be those transferred from another hospital/ward which will allow for \>48 h of hospital contact.

#### Healthcare personnel

Participants screened for *S. aureus* or MRSA fecal carriage working at a healthcare setting with or without any illness.

### Developed and developing countries

Countries were categorized as developed or developing countries based on data from the International Monetary Fund (<http://www.imf.org/external/pubs/ft/weo/2015/01/weodata/groups.htm>).

### Antibiotic susceptibility results

The percentage of isolates (obtained from participants with *S. aureus* or MRSA fecal carriage) resistant to each of the antibiotics assayed was calculated from studies that provided adequate data on antibiotic susceptibility test results. Our review noted susceptibility tests results whether or not the respective studies incorporated published guidelines \[such as Clinical Laboratory Standards Institute (CLSI), National Committee on Clinical Laboratory Standards (NCCLS), European Committee on Antimicrobial Susceptibility Testing (EUCAST), Antibiogram Committee of the French Society of Microbiology (CA-SFM), or the Swedish Reference Group for Antibiotics (SRGA) guidelines\] in assessing the antibiotic resistance profiles.

Statistical analysis and data visualization
-------------------------------------------

The *S. aureus*, MRSA and MSSA fecal carriage rates for studies included in this systematic review were calculated as follows: $$\begin{array}{l}
{S.\, aureus\text{ fecal~carriage~rate~}(\%) =} \\
{\text{~~~~~~~~~~~~~~~~}\frac{\text{Participants~positive~for }S.\, aureus\text{ fecal~carriage}}{\text{Participants~screened~for }S.\, aureus\text{ fecal~carriage}}} \\
{\text{MRSA~fecal~carriage~rate~}(\%) =} \\
{\quad\frac{\text{Participants~positive~for~MRSA~fecal~carriage}}{\text{Participants~screened~for }S.\, aureus\text{ or MRSA~fecal~carriage}}} \\
{\text{MSSA~fecal~carriage~rate~}(\%) =} \\
{\text{\quad\quad\quad}\frac{\begin{array}{l}
{(\text{Participants~positive~for }S.\, aureus\text{ fecal~carriage}} \\
{\text{\quad\quad-~Participants~positive~for~MRSA~fecal~carriage})} \\
\end{array}}{\text{Participants~screened~for }S.\, aureus\text{ fecal~carriage}}} \\
\end{array}$$ Individual reports assessing the same participants for *S. aureus*, MSSA or MRSA fecal carriage were considered as a single report. Calculated fecal *S. aureus* carriage rates were used to derive longitudinal data of individual studies, as well as the average carriage rate amongst these studies, at each time-point. Meta-analyses of proportions were performed to determine the overall *S. aureus*, MSSA and MRSA fecal carriage rates (pooled estimates) among individuals in the community and healthcare settings. Meta-analyses of proportions for MRSA and MSSA did not include studies for which MRSA was not confirmed using molecular methods. For all meta-analyses of proportions, studies screening for MRSA amongst pre-selected vancomycin resistant enterococci (VRE) fecal carriers were excluded. Similarly, meta-analyses of proportions did not include studies that screened for MRSA fecal carriage solely from pre-selected MRSA carriers (MRSA identified from other body sites). Meta-analyses were performed using StatsDirect statistical software version 3.0.165 \[England: StatsDirect Ltd. 2016\] for studies adhering to the inclusion criteria summarized in Table [2](#T2){ref-type="table"}. The StatsDirect statistical software version 3.0.165 \[England: StatsDirect Ltd. 2016\] was also applied to assess the heterogeneity between the studies included in the meta-analyses (Cochran *Q*-test) (Cochran, [@B19]) and to determine the inconsistency across the studies included (*I*^2^ statistic) (Higgins et al., [@B35]). The criterion for statistical significance for the test for heterogeneity was set at alpha = 0.05. The risk of publication bias was assessed and visualized by a Funnel plot (Egger et al., [@B26]; Sterne et al., [@B75]).

Results {#s3}
=======

Study selection and characteristics
-----------------------------------

### *S. aureus* study selection

Figure [1](#F1){ref-type="fig"} outlines the study selection process and the broad reasons for exclusion. The search strategy identified 2522 records. An additional record was identified from the reference list of one of the eligible articles included in the review. A total of 124 potentially eligible reports were identified, of which 69 fulfilled the primary inclusion criteria (Figure [1](#F1){ref-type="fig"}). The vast majority (80%; 55/69) of these potentially eligible articles did not provide information on healthcare exposure during the year preceding screening and/or did not indicate the duration for which patients were admitted prior to the time of screening. Following correspondence with authors, seven articles were excluded as these reports did not fulfill our inclusion criteria. Moreover, 36 articles were excluded due to lack of required information from corresponding authors or as a result of unavailable author contact information. Consequently, only 26 (11 and 15 reports based on their full texts and information obtained from the authors, respectively) of the 69 studies could be included in our systematic review. The main findings reported by each of the 26 eligible studies are summarized in detail in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. Select studies that screened for *S. aureus* fecal carriage from both community and healthcare settings are also reported accordingly in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}.

![**Study selection**. Flow diagram of identification and selection process for studies included in the systematic review.](fmicb-07-00449-g0001){#F1}

###### 

**Characteristics of eligible studies analysing fecal carriage of *Staphylococcus aureus* or MRSA from the community**.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study population setting**         **Participants screened for fecal[^Ψ^](#TN1){ref-type="table-fn"} carriage (n)**   **Participant characteristics**                      **Sample collection**                                                                             **Laboratory technique(s)**                             ***S. aureus* detection**   **MRSA detection**                          **References**                                                                                                                                                                                                                           
  ------------------------------------ ---------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------- --------------------------- ------------------------------------------- ------------------------------------------------------ -------------------------- -------------------------- ---------------------- --------- --------------------------------------------- -------------------------------------------- --------------------------------
  **CATEGORY: HEALTHY PARTICIPANTS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Italy                                100                                                                                Birth to 12 months                                   Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days                                      Delivery unit                                          Phenotypic                 NP                         RAPD                   SE\       5 (5/100)[^φ^](#TN4){ref-type="table-fn"}     NA                                           Lindberg et al., [@B46]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     TSST                                                                                                 

                                                                                                                                                                                                                                                                                                                                         Feces                       1 week                                      Home                                                                                                                                          15 (15/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   24 (24/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                   34 (34/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                   45 (45/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     6 months                                                                                                                                                                                  52 (52/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     1 year                                                                                                                                                                                    31 (27/86)[^φ^](#TN4){ref-type="table-fn"}                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        66 (66/100)[^φ^](#TN4){ref-type="table-fn"}                                                

  Mozambique                           121                                                                                ≤14 days to 1 year                                   Apparently healthy                                                                                NR                                                      Feces                       ≤14 days to 1 year                          Home                                                   Molecular                  NP                         NP                     NP        77 (92/120)                                   NA                                           González et al., [@B32]

  Nigeria                              120                                                                                15--35 years                                         Healthy                                                                                           No                                                      Feces                       15 to 35 years                              Provided by participants                               Phenotypic                 Phenotypic                 NP                     NP        32 (38/120)                                   34 (13/38)[^¶^](#TN3){ref-type="table-fn"}   Onanuga and Temedie, [@B58]

  Spain                                21                                                                                 7--35 days                                           Healthy                                                                                           At time of delivery[^φ^](#TN4){ref-type="table-fn"}     Feces                       1 week\                                     Home                                                   Phenotypic and Molecular   Phenotypic and Molecular   *spa* typing\          SE\       10 (2/21)\                                                                                 Benito et al., [@B9]
                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                  *agr* typing           PVL       14 (3/21)                                                                                  

                                                                                                                                                                                                                                                                                                                                                                     5 weeks                                                                                                                                                  MLST                   ET        48 (10/21)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                       PFGE                   TSST      57 (12/21)                                    42 (5/12)                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AUR                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     BAP                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CNA                                                                                                  

  Spain                                100                                                                                2--89 years                                          Healthy                                                                                           No[^φ^](#TN4){ref-type="table-fn"}                      Feces                       2--89 years                                 NR                                                     Phenotypic and Molecular   Phenotypic and Molecular   *spa* typing\          SE\       15 (15/100)                                   0 (0/15)                                     Benito et al., [@B8]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *agr* typing           PVL                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              MLST                   ET                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     TSST                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AUR                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     BAP                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     CNA                                                                                                  

  Spain                                50                                                                                 7--23 months                                         Healthy                                                                                           At time of delivery[^φ^](#TN4){ref-type="table-fn"}     Feces                       7--23 months                                Nurseries                                              Phenotypic and Molecular   Phenotypic and Molecular   NP                     NP        6 (3/50)                                      0 (0/3)                                      Domínguez et al., [@B22]

  Sweden                               100                                                                                Birth to 12 months                                   Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days                                      Delivery unit                                          Phenotypic                 NP                         RAPD                   SE TSST   16 (16/100)[^φ^](#TN4){ref-type="table-fn"}   NA                                           Lindberg et al., [@B46]

                                                                                                                                                                                                                                                                                                                                         Feces                       1 week                                      Home                                                                                                                                          48 (48/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   56 (56/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                   64 (64/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                   72 (72/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     6 months                                                                                                                                                                                  68 (68/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     1 year                                                                                                                                                                                    55 (55/100)[^φ^](#TN4){ref-type="table-fn"}                                                

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        78 (78/100)[^φ^](#TN4){ref-type="table-fn"}                                                

  Sweden                               64                                                                                 Birth to 8 weeks                                     Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days[^φ^](#TN4){ref-type="table-fn"}      Delivery unit[^φ^](#TN4){ref-type="table-fn"}          Phenotypic                 NP                         NP                     SE TSST   13 (8/64)[^φ^](#TN4){ref-type="table-fn"}     NA                                           Lundell et al., [@B50]

                                                                                                                                                                                                                                                                                                                                         Feces                       1 week                                      Home[^φ^](#TN4){ref-type="table-fn"}                                                                                                          39 (25/64)[^φ^](#TN4){ref-type="table-fn"}                                                 

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   53 (33/62)[^φ^](#TN4){ref-type="table-fn"}                                                 

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                   59 (37/63)[^φ^](#TN4){ref-type="table-fn"}                                                 

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                   71 (44/62)[^φ^](#TN4){ref-type="table-fn"}                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        73 (47/64)[^φ^](#TN4){ref-type="table-fn"}                                                 

  Sweden                               50                                                                                 Birth to 12 months                                   Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days                                      Delivery unit                                          Phenotypic                 NP                         RAPD                   ET        20 (10/50)                                    NA                                           Lindberg et al., [@B45]

                                                                                                                                                                                                                                                                                                                                                                     1 week                                      Home                                                                                                         PFGE                   TSST      40 (20/50)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   52 (26/50)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                   60 (30/50)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                   64 (32/50)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        68 (34/50)                                                                                 

                                       37                                                                                 Apparently healthy[^φ^](#TN4){ref-type="table-fn"}   Allergic and non-allergic mothers                                                                 At time of delivery                                     Feces                       1 week after delivery or at a later stage   Home                                                                                                                                          24 (9/37)                                     NA                                           

  Sweden                               81                                                                                 Birth to 12 months                                   Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days                                      Delivery unit at 3 days and home at 1 week to 1 year   Phenotypic                 Phenotypic                 RAPD                   ET\       NR                                            0 (0/81)[^φ^](#TN4){ref-type="table-fn"}     Lindberg et al., [@B47]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     TSST                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     1 week                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                     6 months                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                     1 year                                                                                                                                                                                                                                                                               

  Sweden                               49                                                                                 Birth to 12 months                                   Healthy                                                                                           At time of delivery                                     Rectal swabs                3 days                                      Delivery unit                                          Phenotypic                 NP                         RAPD                   ET TSST   16 (8/49)                                     NA                                           Lindberg et al., [@B48]

                                                                                                                                                                                                                                                                                                                                         Feces                       1 week                                      Home                                                                                                                                          57 (28/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   65 (32/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     4 weeks                                                                                                                                                                                   65 (32/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     8 weeks                                                                                                                                                                                   73 (36/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     6 months                                                                                                                                                                                  73 (36/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     1 year                                                                                                                                                                                    53 (26/49)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        86 (42/49)[^φ^](#TN4){ref-type="table-fn"}                                                 

  United Kingdom                       30                                                                                 2--7 months                                          Healthy                                                                                           NR                                                      Feces                       2 weeks                                     Home                                                   Phenotypic                 NP                         NP                     SE TSST   37 (11/30)                                    NA                                           Harrison et al., [@B34]

                                                                                                                                                                                                                                                                                                                                                                     10 weeks                                                                                                                                                                                  40 (12/30)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     7 months                                                                                                                                                                                  40 (12/30)                                                                                 

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        40 (12/30)                                                                                 

  United States of America             147                                                                                \>18 years                                           Healthy pregnant women at 35-37 weeks of pregnancy                                                No[^φ^](#TN4){ref-type="table-fn"}                      Rectal swabs                \>18 years                                  Obstetric clinics                                      Phenotypic                 Phenotypic and Molecular   SCC*mec* typing PFGE   PVL       4 (6/147)[^φ^](#TN4){ref-type="table-fn"}     0 (0/6)[^φ^](#TN4){ref-type="table-fn"}      Andrews et al., [@B4]

  United States of America             38                                                                                 1 day to 2 weeks                                     Healthy                                                                                           At time of delivery                                     Feces                       1--2 days                                   New-born unit                                          Phenotypic                 Phenotypic and Molecular   PFGE                   PVL       0 (0/38)                                      0 (0/38)                                     Gries et al., [@B33]

                                                                                                                                                                                                                                                                                                                                                                     2 weeks                                                                                                                                                                                   26 (6/23)                                     33 (2/6)                                     

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        26 (6/23)                                     33 (2/6)                                     

  **CATEGORY: OUTPATIENTS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  India                                100                                                                                16--88 years                                         Patients at admission                                                                             No long hospital stay or admission to other hospitals   Feces                       16--88 years                                Hospital                                               Phenotypic                 NP                         NP                     NP        0 (0/100)                                     NA                                           Deepa et al., [@B21]

  Jordan                               216                                                                                ≤28 days to 1 year                                   NR                                                                                                No                                                      Feces                       ≤28 days to 1 year                          Clinic                                                 Phenotypic                 Phenotypic                 SCC*mec* typing        ET        17 (37/216)                                   59 (22/37)                                   Shehabi et al., [@B66]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PVL                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     SE                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     TSST                                                                                                 

  Nigeria                              1761                                                                               ≤5 years                                             Diarrhoeic children                                                                               No[^φ^](#TN4){ref-type="table-fn"}                      Feces                       \< 1 year                                   Hospital                                               Phenotypic                 Phenotypic                 NP                     ET        3 (11/416)                                    NR                                           Efuntoye and Adetosoye, [@B25]

                                                                                                                                                                                                                                                                                                                                                                     1.1--2.0 years                                                                                                                                                                            4 (13/323)                                    NR                                           

                                                                                                                                                                                                                                                                                                                                                                     2.1--3.0 years                                                                                                                                                                            4 (12/309)                                    NR                                           

                                                                                                                                                                                                                                                                                                                                                                     3.1--4.0 years                                                                                                                                                                            5 (15/292)                                    NR                                           

                                                                                                                                                                                                                                                                                                                                                                     4.1--5.0 years                                                                                                                                                                            5 (21/421)                                    NR                                           

                                                                                                                                                                                                                                                                                                                                                                     Overall prevalence                                                                                                                                                                        4 (72/1761)                                   NR                                           

  Saudi Arabia                         58                                                                                 NR                                                   Patients at admission (\< 48 h)[^φ^](#TN4){ref-type="table-fn"} with diarrhea or abdominal pain   No[^φ^](#TN4){ref-type="table-fn"}                      Feces                       NR                                          Hospital                                               Phenotypic                 Phenotypic                 NP                     NP        NA                                            9 (5/58)                                     Babay and Somily, [@B6]

  United States of America             150                                                                                Birth to 18 years                                    Children requiring abscess drainage (n = 60)                                                      No[^φ^](#TN4){ref-type="table-fn"}                      Rectal swabs                Birth to 18 years                           Hospital                                               Phenotypic and Molecular   Molecular                  MLVA SCC*mec* typing   PVL       47 (28/60)                                    NR                                           Faden et al., [@B28]

                                                                                                                                                                               Children requiring general surgery (n = 90)                                                                                                                                                                                                                                                                                                                                     1 (1/90)                                      NR                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fecal samples, rectal swabs, anal swabs, peri-rectal or peri-anal swabs.

Hospital, long-term care facility, nursing homes, maternity wards.

Resistant to cefoxitin.

Information obtained from the author.

Phenotypic identification: culture characteristics on mannitol salt agar, Baird-Parker agar, Tripticase soy agar, Chapman agar, Staphylococcus medium 110, positive results for Gram stain, catalase, coagulase and DNase Tests.

agr, Accessory gene regulator; AUR, Aureolysisn; BAP, biofilm-associated protein; CAN, collagen-binding protein; ET, Exfoliative toxins; MLVA, Multiple-locus variable-number tandem repeat analysis; MRSA, methicillin resistant Staphylococcus aureus; NR, Not reported; NP, Not performed; NA, Not applicable; PFGE, pulsed-field gel electrophoresis; PVL, Panton-Valentine Leukocidin; RAPD, random amplified polymorphic DNA; SCCmec, staphylococcal cassette chromosome mec; SE, Staphylococcal enterotoxins; spa, Staphylococcus aureus protein A; TSST, Toxic shock syndrome toxin.

###### 

**Characteristics of eligible studies analysing fecal carriage of *Staphylococcus aureus* or MRSA from the healthcare setting**.

  **Study population setting**         **Participants screened for fecal[^Ψ^](#TN5){ref-type="table-fn"} carriage (n)**   **Participant characteristics**   **Sample collection**                                                                                          **Laboratory technique(s)**                                                                                      ***S. aureus* detection**   **MRSA detection**      **Reference**                                                                                                                                                                                   
  ------------------------------------ ---------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------- ---------------------- -------------------------- -------------------------- ----------------- ------ ------------------------------------------ ---------------------------------------------- --------------------------------
  **CATEGORY: IN-PATIENTS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  France                               748                                                                                Mean age: 55 years±12             Liver cirrhosis                                                                                                Hospitalized for minimum of 2 weeks                                                                              Feces                       Mean age: 55 years±12   Hospital               Phenotypic                 Phenotypic                 NP                NP     NR                                         12 (93/748)                                    Campillo et al., [@B17]
  France                               327                                                                                NR                                Chronic liver disease, post-surgical patients, patients with alcohol withdrawal and digestive tract diseases   Patients transferred from other hospitals                                                                        Feces                       NR                      Hospital               Phenotypic and Molecular   Phenotypic                 PFGE              NP     NR                                         11 (36/327)                                    Dupeyron et al., [@B24]
  Germany                              2727                                                                               NR                                Nosocomial diarrhea                                                                                            ≥72 h at the time of study                                                                                       Feces                       NR                      Hospital               Phenotypic                 Phenotypic                 NP                SE     7 (198/2727)                               15 (29/198)                                    Flemming and Ackermann, [@B30]
  Germany                              131                                                                                NR                                NR                                                                                                             Inpatients positive for MRSA                                                                                     Rectal swabs                NR                      Hospital               Phenotypic and Molecular   Phenotypic and Molecular   PFGE              SE     NR                                         47 (61/131)                                    Klotz et al., [@B41]
  Jordan                               214                                                                                ≤28 days to 1 year                NR                                                                                                             NR                                                                                                               Feces                       ≤28 days to 1 year      NICU                   Phenotypic                 Phenotypic                 SCC*mec* typing   ET     2 (5/214)                                  20 (1/5)                                       Shehabi et al., [@B66]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               PVL                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               SE                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               TSST                                                                                             
  Saudi Arabia                         122                                                                                NR                                NR                                                                                                             ≥72 h at the time of study                                                                                       Feces                       NR                      Hospital               Phenotypic                 Phenotypic                 NP                NP     NA                                         7 (9/122)                                      Babay and Somily, [@B6]
  United States of America             810 (2000-01)                                                                      NR                                Cancer                                                                                                         Inpatients[^φ^](#TN7){ref-type="table-fn"}                                                                       Rectal swabs                NR                      Hospital               Phenotypic and Molecular   Phenotypic                 *spa* typing      PVL    NR                                         0.6 (5/810)[^φ^](#TN7){ref-type="table-fn"}    Srinivasan et al., [@B73]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             MLST                                                                                                               
                                       925 (2006-07)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         PFGE                                                                2.9 (27/925)[^φ^](#TN7){ref-type="table-fn"}   
  United States of America             161                                                                                57--103 years                     Fecal and urinary in-continence, pressure ulcers, diabetes, COPD, heart failure                                Long-term care facility residents                                                                                Rectal swabs                57-103 years            Long-term care wards   NP                         Phenotypic                 PFGE              NP     NA                                         3 (4/161)                                      O\'Fallon et al., [@B57]
  United States of America             37                                                                                 48--91 years                      Chronic renal failure, diabetes, chronic dermato-logic infections                                              Inpatients positive for VRE                                                                                      Feces                       48 to 91 years          Hospital               Phenotypic                 Phenotypic                 PFGE              NP     62 (23/37)                                 87 (20/23)                                     Ray et al., [@B62]
  United States of America             114                                                                                NR                                NR                                                                                                             Skilled-care patients admitted for long-term care                                                                Rectal swabs                                        Hospital               Phenotypic                 Phenotypic                 PFGE              NP     NR                                         5 (6/114)                                      Trick et al., [@B79]
  **CATEGORY: HEALTHCARE PERSONNEL**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  United States of America             62                                                                                 \>18 years                        Healthy pregnant women at 35--37 weeks of pregnancy                                                            No[^φ^](#TN7){ref-type="table-fn"}                                                                               Rectal swabs                \> 18 years             Obstetric clinics      Phenotypic                 Phenotypic and Molecular   SCC*mec* typing   PVL    3 (2/62)[^φ^](#TN7){ref-type="table-fn"}   0 (0/2)[^φ^](#TN7){ref-type="table-fn"}        Andrews et al., [@B4]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PFGE                                                                                                               
  United States of America             55                                                                                 36 years±11                       NR                                                                                                             Nurses (n = 29), Physicians (n = 15), Others (n = 9), Unknown (n = 2) (mean patient contact years: 13 years±9)   Fecal                       36 years±11             NR                     NP                         Phenotypic                 NP                NP     NA                                         0 (0/55)                                       Carmeli et al., [@B18]

Fecal samples, rectal swabs, anal swabs, peri-rectal or peri-anal swabs.

Hospital, long-term care facility, nursing homes, maternity wards.

Information obtained from the author.

Phenotypic identification: culture characteristics on mannitol salt agar, Baird-Parker agar, Tripticase soy agar, Chapman agar, Staphylococcus medium 110, positive results for Gram stain, catalase, coagulase and DNase Tests.

agr, Accessory gene regulator; AUR, Aureolysisn; BAP, biofilm-associated protein; CNA, collagen-binding protein; COPD, chronic obstructive pulmonary disorder; ET, Exfoliative toxins; MLVA, Multiple-locus variable-number tandem repeat analysis; MRSA, methicillin resistant Staphylococcus aureus; NICU, Neonatal intensive care unit; NR, Not reported; NP, Not performed; NA, Not applicable; PFGE: pulsed-field gel electrophoresis; PVL, Panton-Valentine Leukocidin; SCCmec, staphylococcal cassette chromosome mec; SE, Staphylococcal enterotoxins; spa, Staphylococcus aureus protein A; TSST, Toxic shock syndrome toxin; VRE, Vancomycin-resistance enterococci.

### Characteristics of reports from community and healthcare settings

#### Reports on *S. aureus* fecal carriage

A total of 19 reports investigated fecal *S. aureus* carriage within the community setting, of which five and 14 studies reported on fecal carriage rates from outpatients and healthy participants, respectively (Table [3](#T3){ref-type="table"}). Moreover, the majority (64%; 9/14) of reports on fecal *S. aureus* carriage rates from healthy participants were of longitudinal design and investigated infants up until one year of age (Table [3](#T3){ref-type="table"}). Of the five reports on fecal carriage rates from outpatients, a single study performed a longitudinal analysis of *S. aureus* fecal carriage (Efuntoye and Adetosoye, [@B25]) and another investigated infants during the first year of life (Shehabi et al., [@B66]). Study sizes for the community setting ranged between 21 and 1761 participants (Table [3](#T3){ref-type="table"}).

Fecal *S. aureus* carriage within the healthcare setting was noted in 12 reports (Table [4](#T4){ref-type="table"}). Of these, 10 were from inpatients and two from healthcare personnel. All reports on inpatients were of cross-sectional design and the majority (60%; 6/10) did not provide information on the age of the participants. In addition, the two studies on healthcare personnel were cross-sectional in design and carried out in the United States of America (USA) (Carmeli et al., [@B18]; Andrews et al., [@B4]). Study sizes for healthcare-based reports ranged between 37 and 2727 participants (Table [4](#T4){ref-type="table"}).

#### Reports on methicillin susceptible and resistant *S. aureus* fecal carriage

Six of the 19 reports on *S. aureus* fecal carriage from the community setting provided MRSA fecal carriage rates confirmed by molecular methods (Table [3](#T3){ref-type="table"}). Five of these studies (conducted in developed countries) reported both *S. aureus* and MRSA fecal carriage rates which allowed for the calculation of MSSA fecal carriage rates. Only one study within the healthcare setting (conducted in the USA) confirmed fecal MRSA carriage by screening specimens using a molecular approach (Andrews et al., [@B4]).

Pooled estimates of *S. aureus* fecal carriage rates assessed by meta-analyses
------------------------------------------------------------------------------

Studies included in all of the proportional meta-analyses were heterogeneous, as determined by the Cochrane Q test and *I*^2^ statistic (Figures [2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}). We could not determine pooled MSSA or MRSA fecal carriage rates within the healthcare setting as only a single study was considered eligible for this analysis.

![**Bias assessment (Funnel) plot for studies assessing *Staphylococcus aureus* fecal carriage rates**.](fmicb-07-00449-g0002){#F2}

![**Bias assessment (Funnel) plot for studies assessing Methicillin susceptible *Staphylococcus aureus* fecal carriage rates**.](fmicb-07-00449-g0003){#F3}

![**Bias assessment (Funnel) plot for studies assessing Methicillin resistant *Staphylococcus aureus* fecal carriage rates**.](fmicb-07-00449-g0004){#F4}

The pooled random-effects estimate for *S. aureus* fecal carriage within the community and healthcare settings was 26% (95% *CI* = 16.8--36.3; Figure [5](#F5){ref-type="fig"}). Sub-analyses of *S. aureus* fecal carriage within the community and healthcare settings resulted in pooled random-effects estimates of 31% (95% *CI* = 17.8--46.3) and 5% (95% CI = 1.7--8.9), respectively.

![**Meta-analysis of proportions on *S. aureus* fecal carriage rates**. \*, Community setting; +, Healthcare setting; H, Healthy participants; O, Outpatients; I, Inpatients; HP, Healthcare personnel.](fmicb-07-00449-g0005){#F5}

MSSA fecal carriage was estimated at 86% (95% *CI* = 65.9--97.9) using the random-effects model (Figure [6](#F6){ref-type="fig"}). Within the community setting, the random effects estimate for MSSA fecal carriage was 86% (95% *CI* = 62.3--98.5). The pooled random-effects estimates for MRSA fecal carriage were 10% (95% *CI* = 0.7--27.0; Figure [7](#F7){ref-type="fig"}); and 10% (95% *CI* = 0.4--28.9) within the community setting.

![**Meta-analyses of proportions on Methicillin susceptible *Staphylococcus aureus* fecal carriage rates**. Pooled random-effects estimate of MSSA fecal carriage within the community and healthcare setting. \*, Community setting; +, Healthcare setting; H, Healthy participants; HP, Healthcare personnel.](fmicb-07-00449-g0006){#F6}

![**Meta-analyses of proportions on Methicillin resistant *Staphylococcus aureus* fecal carriage rates**. Pooled random effects estimate of MRSA fecal carriage within community and healthcare settings. \*, Community setting; +, Healthcare setting; H, Healthy participants; HP, Healthcare personnel.](fmicb-07-00449-g0007){#F7}

*S. aureus* fecal carriage rates according to the age of participants
---------------------------------------------------------------------

The report on this section is not based on meta-analysis. *S. aureus* fecal carriage rates within the community setting were higher during the first year of life (Figure [8](#F8){ref-type="fig"}). On average, reports from longitudinal studies revealed an increase in *S. aureus* fecal carriage rates from approximately 10--65% during the first 8 weeks of life (Figure [8](#F8){ref-type="fig"}). At 6 months of age, the average fecal carriage rate was 64%, thereafter it decreased to approximately 46% at 1 year of life. A longitudinal investigation of fecal MRSA carriage rates from healthy participants from the USA showed an increase in fecal MRSA carriage from 0 to 9% during the first 2 weeks of life (Gries et al., [@B33]). The highest MRSA fecal carriage rate (23%) reported was from Spanish infants screened at ≤1 year of life (Benito et al., [@B9]).

![**Longitudinal *S. aureus* fecal carriage rates during the first year of life**. The lines in color indicated fecal carriage rates (%) at each of the time-points measured by the respective studies. The different cohorts are shown by different symbols at each of the time-points studied. The black broken line is the average fecal *S. aureus* carriage rate calculated from all longitudinal studies at the respective time-points under study.](fmicb-07-00449-g0008){#F8}

Assessment of antibiotic susceptibility of fecal *S. aureus* isolates
---------------------------------------------------------------------

Eight of the 26 eligible studies (31%) included in this review assayed for antibiotic susceptibility of fecal *S. aureus* or MRSA isolates (Table [5](#T5){ref-type="table"}). Overall, *S. aureus* or MRSA isolates were screened with 32 different antibiotics across the respective studies using disk diffusion, agar dilution, or the Vitek Legacy System. The use of published guidelines for susceptibility testing were reported by six of the eight studies (Table [5](#T5){ref-type="table"}). Susceptibility testing to erythromycin was performed most frequently (88%; 7/8), followed by chloramphenicol, clindamycin, ciprofloxacin, gentamicin, penicillin and vancomycin (75%; 6/8) (Table [5](#T5){ref-type="table"}). Vancomycin intermediate or resistant *S. aureus* (VISA/VRSA) were not identified in five of the six studies that screened for vancomycin resistance (Table [5](#T5){ref-type="table"}). Only the study by Onanuga and Temedie ([@B58]) reported fecal VRSA carriage of 37% (14/38).

###### 

**Antibiotic resistance profiles across participants screened for fecal *S. aureus* or MRSA**.

  **Study**                        **Guide-lines applied**   **Techniques applied**                    **Total number of *S. aureus* or MRSA isolates screened for resistance**   **Antibiotic resistance profiles of fecal S. aureus or MRSA isolates (%)**                                                                                                                                                
  -------------------------------- ------------------------- ----------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---- ---- ---- ---- ---- ----- ---- --- --- ---- --- --- ---- ---- ---- ---- ---- --- --- ---- --- ----- ---- ---- --- --- ---- --- --- ---- ---
  Domínguez et al., [@B22]         NR                        Agar dilution method                      3                                                                                                                                                       0    0    0    0                        0            0   0    0              67                    100   0    0                              0
  Efuntoye and Adetosoye, [@B25]   NCCLS                     Disk diffusion method                     72                                                                                                                                                           22                             0                         9    99   99   67           79   7   100        0                              
  Lindberg et al., [@B47]          SRGA                      Disk diffusion method                     116                                                                                                                                                     0              0                        0            0   0    1              3                     78    0    0        0            1        2
  Flemming and Ackermann, [@B30]   NR                        Disk diffusion method                     198                                                                                                                                                                                                                                                              15                                  
  Srinivasan et al., [@B73]        CLSI                      Vitek Legacy System                       31[^\*^](#TN8){ref-type="table-fn"}                                                                                                                     3                        100            0   32           0    32             81                    100             0       3                 
  Onanuga and Temedie, [@B58]      CLSI                      Disk diffusion and agar dilution method   38                                                                         0                                                                            5                   18   34    24       8        8       37                  34   0       68                  34           37   0       61   
  Benito et al., [@B8]             CLSI CA-SFM               Disk diffusion method                     15                                                                                                                                                      0    0    0    7         0              0                0    20             20       0            60    0    0    7       0        0        0
  Benito et al., [@B9]             CLSI EUCAST               Disk diffusion method                     25                                                                                                                                                      36   0    16   36        40             4                0    32             36       0            40    40   0    0       0        4        0

(CA-SFM), Antibiogram Committee of the French Society of Microbiology; (CLSI), Clinical Laboratory Standards Institute; (EUCAST), European Committee on Antimicrobial Susceptibility; (NCCLS), National Committee on Clinical Laboratory Standards; (SRGA), Swedish Reference Group for Antibiotics; NR, Not reported.

Number of MRSA isolates (detected using oxacillin screening agar) screened for antibiotic resistance

Antibiotic resistance rates (%): ![](fmicb-07-00449-i0001.jpg) 0; ![](fmicb-07-00449-i0002.jpg) \> 0--10; ![](fmicb-07-00449-i0003.jpg) \> 10--20; ![](fmicb-07-00449-i0004.jpg) \> 20--30; ![](fmicb-07-00449-i0005.jpg) \> 30--40; ![](fmicb-07-00449-i0006.jpg) \> 40--50; ![](fmicb-07-00449-i0007.jpg) \> 50--60; ![](fmicb-07-00449-i0008.jpg) \> 60--70; ![](fmicb-07-00449-i0009.jpg) \> 70--80; ![](fmicb-07-00449-i0010.jpg) \> 80--90; ![](fmicb-07-00449-i0011.jpg) \> 90--100.

Genotyping of *S. aureus* isolated from fecal specimens
-------------------------------------------------------

Techniques used to genotype *S. aureus* isolated from fecal specimens included multiple-locus variable-number tandem repeat analysis (MLVA), pulsed-field gel electrophoresis (PFGE), random amplified polymorphic DNA (RAPD) analysis, staphylococcal cassette chromosome *mec* (SCC*mec*), accessory gene regulator (*agr*) and *Staphylococcus aureus* protein A (*spa*) typing (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). Genotyping was performed in slightly more reports from the healthcare setting (67%; 8/12) compared to the community (58%; 11/19). Gel-based methods (PFGE, RAPD and MLVA) were employed in 58% (7/12) and 42% (8/19) of studies in the healthcare and community settings, respectively. In addition, similar rates (26% vs. 25%) in the use of sequence-based methods (*spa* typing, SCC*mec* typing and MLST) for genotyping of *S. aureus* strains were reported from community and healthcare settings. Only a single study conducted in a developing country (Jordan) performed genotyping of the *S. aureus* strains (Shehabi et al., [@B66]).

Assessment of the detection of *S. aureus* virulence genes
----------------------------------------------------------

Virulence genes screened included the aureolysin enzyme, biofilm-associated protein, collagen-binding protein, exfoliative toxins (ETs), staphylococcal enterotoxins (SEs), toxic shock syndrome toxin (TSST), and Panton-Valentine leukocidin (PVL) (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). More community--based investigations screened for *S. aureus* virulence genes compared to reports from the healthcare setting. Thus, 53% (10/19), 37% (7/19), and 37% (7/19) of studies conducted in the community setting reported on TSSTs, SEs, ETs, respectively, using PCR, reverse passive latex agglutination tests or enzyme-linked immunosorbent assays. Approximately one third of the studies conducted in the community setting (6/19) reported on PCR detection of the PVL genes. In studies conducted in the healthcare setting; 8% (1/12), 25% (3/12.), 8% (1/12), and 25% (3/12) reported on TSSTs, SEs, ETs, and PVL, respectively.

*S. aureus* and MRSA fecal carriage as risk factors for disease development
---------------------------------------------------------------------------

Two studies included in this review identified enterotoxin producing *S. aureus* strains from fecal specimens of patients with diarrhea (Efuntoye and Adetosoye, [@B25]; Flemming and Ackermann, [@B30]). Another study reported that all patients colonized with MRSA in both the nares and rectum (8/8) developed an infection (Srinivasan et al., [@B73]). In addition, two of the nine patients, colonized with MRSA in the rectum only, were concurrently or subsequently infected. *Spa* typing on a subset of colonizing isolates from the nares and rectum noted that the majority (69%; 9/13) were clonally related to infecting isolates (Srinivasan et al., [@B73]). In support of the potential of fecal carriage for infection, it has also been shown that *S. aureus* detection occurs more frequently from rectal specimens of children with skin and soft tissue abscesses (47%; 28/60) compared with the control group (1%; 1/90) (*P* = 0.0001) (Faden et al., [@B28]).

Discussion {#s4}
==========

Our results clearly showed that fecal *S. aureus* carriage from healthy infants is high during the first year of life. Specifically, *S. aureus* fecal carriage rates increased during the first 8 weeks of life followed by a gradual decrease towards 1 year of life. The reasons for this abrupt increase in fecal carriage very early in life (especially from healthy infants) is not yet clear, however a potential explanation may be early life care-giving practices, particularly breastfeeding. For example, colostrum contains the highest levels of human milk oligosaccharides (HMOs) (Bode, [@B13]), which have been suggested to stimulate *S. aureus* growth (Hunt et al., [@B37]). Moreover, *S. aureus* strains may be transmitted from parents via skin contact (Lindberg et al., [@B45]) or from the mother via breastfeeding (Kawada et al., [@B40]; Lindberg et al., [@B45]; Benito et al., [@B9]). Furthermore, staphylococci from the maternal GIT or skin surrounding the areola may be transferred to breast milk during lactation (Thum et al., [@B77]; Fernández et al., [@B29]). Higher *S. aureus* fecal carriage rates have also been noted from breast-fed in comparison to formula-fed or mixed-fed infants (González et al., [@B32]; Salminen et al., [@B64]). The observed change in the dynamics of *S. aureus* fecal carriage after 8 weeks of life may be explained by the increase in anaerobic bacteria from around 1 week of life (Bezirtzoglou, [@B11]; Adlerberth et al., [@B2]; Adlerberth and Wold, [@B3]; Jost et al., [@B39]), as well as the introduction of formula feeding (González et al., [@B32]) and solid foods (Bergström et al., [@B10]; Voreades et al., [@B82]). Infant fecal bacterial profiles have also been shown to change during the course of the lactation period (Cabrera-Rubio et al., [@B16]; González et al., [@B32]).

This systematic review does not only provide insight into the dynamics of fecal *S. aureus* carriage rates during the first year of life; but also highlights that *S. aureus* and MRSA fecal carriage is a potential risk factor for subsequent infections. Vancomycin is regarded as one of the drugs of choice for MRSA infections (Tarai et al., [@B76]); however the emergence of vancomycin resistant *S. aureus* (VRSA) poses yet another threat to infection control (Hiramatsu, [@B36]; Spagnolo et al., [@B71]). The intestinal tract, in particular, may be a key potential reservoir for the emergence and transmission of VRSA isolates due to the intestinal coexistence (Ray et al., [@B62]), and potential transfer of the *vanA* gene from VRE to MRSA (Courvalin, [@B20]). Although, 23% of the studies included in this review screened for fecal carriage of VRSA within community and healthcare settings (Domínguez et al., [@B22]; Lindberg et al., [@B47]; Srinivasan et al., [@B73]; Onanuga and Temedie, [@B58]; Benito et al., [@B8], [@B9]); only a single study, performed in Nigeria, reported VRSA fecal carriage (Onanuga and Temedie, [@B58]). It is noteworthy, however, that this finding should be interpreted with caution as the disk diffusion method was used to screen for vancomycin resistance at 30 μg/ml, which is not recommended by the CLSI guidelines (Clinical Laboratory Standards Institute, [@B74]).

Healthcare associated fecal screening for *S. aureus* and MRSA is of key importance in infection control (Campillo et al., [@B17]; Ray et al., [@B62]; Bhalla et al., [@B12]). For example, it has been shown that select staphylococcal enterotoxins (SEs) may contribute to the colonizing success of *S. aureus* strains in the GIT (Nowrouzian et al., [@B56]), which could potentially facilitate in its transmission. Moreover, *S. aureus* and MRSA fecal carriage may complicate de-colonization, with a potential to contribute to infections within the healthcare setting (Campillo et al., [@B17]; Dupeyron et al., [@B24]; Ray et al., [@B62]; Srinivasan et al., [@B73]). To prevent nosocomial transmission and infection, two recent studies (Roth et al., [@B63]; Senn et al., [@B65]) have also highlighted the importance of screening for *S. aureus* fecal carriage on admission in the following risk groups: patients admitted to surgery or intensive care units with a history of MRSA colonization or infection; hospitalization during the past year; or direct transfer from another healthcare facility. Only a single study was considered eligible for inclusion in our meta-analyses of the proportions on MSSA and MRSA fecal carriage within the healthcare setting. Therefore we could not determine the fecal carriage rate for MSSA or MRSA within this setting.

A major limitation in this systematic review is the poor study design and limited data available from studies assessing the fecal carriage rates of *S. aureus* and MRSA. For example, a large proportion of potentially eligible articles were excluded due to the lack of information regarding participants\' contact with healthcare facilities as well as the duration of hospital admission prior to *S. aureus* and MRSA screening. This information is essential in comparing fecal carriage rates from community and healthcare settings. Furthermore, a number of studies could not be included in calculating the pooled estimates for MSSA and MRSA fecal carriage (from both community and healthcare settings) due to the lack of molecular techniques incorporated to confirm MRSA carriage. On the other hand, the extent in which our observations could have changed if unavailable articles were included is unclear. However, based on the rigorous appraisal of various studies in this systematic review, we conclude that the excluded articles are not likely to impact significantly on observations presented in the manuscript. In addition, more studies from both developed and developing countries are needed in order to determine *S. aureus* and MRSA fecal carriage and transmission within and between the community and healthcare settings. In support of this, rural areas and low socioeconomic status have been shown to contribute to higher fecal transmission rates of *S. aureus* and MRSA (Vale and Vítor, [@B80]). Finally, there is the need for more sequence-based genotyping data on *S. aureus* and MRSA fecal carriage as the majority of studies from developed countries made use of gel-based methods which are not ideal when comparing isolates on a global level.

Conclusion {#s5}
==========

*S. aureus*, MSSA and MRSA fecal carriage rates within both the community and healthcare setting are not negligible and estimated at 26, 86, and 10%, respectively. Therefore, preventative strategies which include fecal *S. aureus* screening of high risk patients are necessary for infection control within these settings. More studies are needed to determine the role of fecal *S. aureus* carriage as a risk factor for disease development; as well as fecal carriage rates of MSSA, MRSA, and VRSA from both community and healthcare settings. Furthermore, well-structured research should be conducted and sequence-based genotyping techniques should be employed. The latter will allow for comparison of isolates on a global level in both developing and developed countries.
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